Hemophilia Treatment Market by Drugs, Distribution Channels, Trends and Forecast to 2021

Haemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. The three forms of hemophilia are hemophilia A, B, and C. Haemophilia isn’t curable, but it can be treated to minimize symptoms and prevent future health complications. The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII (FVIII) inhibitors, and treatment and rehabilitation of hemophilia synovitis. Hemophilia is treated by replacing the protein that is missing in the blood. All products available to treat hemophilia need to be injected directly into the bloodstream. The preferred treatment for hemophilia is factor replacement therapy. Concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein. Plasma derived factor concentrates that are made from human blood. Blood contains plasma, which contains proteins, antibodies, albumin and clotting factors, while recombinant factor concentrates are manufactured using hamster cells. Antifibrinolytic medicines (including tranexamic acid and epsilon aminocaproic acid) may be used with replacement therapy. They're usually given as a pill, and they help keep blood clots from breaking down. Desmopressin (DDAVP) is a man-made hormone used to treat people who have mild hemophilia A. DDAVP isn't used to treat hemophilia B or severe hemophilia A.

Visit Hemophilia Treatment Market by Drug Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination, Recombinant Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination), Indication Type (Acquired Hemophilia, Hemophilia A, Hemophilia B, Hemophilia C), and Distribution Channel (E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/

The global hemophilia treatment market segmentation is based on drug type (antifibrinolytic agents, desmopressin, plasma derived coagulation factor concentrates - factor VIII, factor IX, combination, recombinant coagulation factor concentrates - factor VIII, factor IX, combination), indication type (acquired hemophilia, hemophilia a, hemophilia b, hemophilia c), and distribution channel (e-commerce, hospital pharmacies, retail pharmacies).

The global hemophilia treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hemophilia treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hemophilia treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global hemophilia treatment market and included in this report are Bayer AG, Biogen, Biotest AG, CSL Behring, F. Hoffmann-La Roche Ltd., Kedrion, Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., and Shire Plc.

1. Drug Type
1.1. Antifibrinolytic Agents
1.2. Desmopressin
1.3. Plasma Derived Coagulation Factor Concentrates
1.3.1. Factor VIII
1.3.2. Factor IX
1.3.3. Combination
1.4. Recombinant Coagulation Factor Concentrates
1.4.1. Factor VIII
1.4.2. Factor IX
1.4.3. Combination

2. Indication Type
2.1. Acquired Hemophilia
2.2. Hemophilia A
2.3. Hemophilia B
2.4. Hemophilia C

3. Distribution Channel
3.1. E-commerce
3.2. Hospital Pharmacies
3.3. Retail Pharmacies

4. Company Profiles
4.1. Bayer AG
4.2. Biogen
4.3. Biotest AG
4.4. CSL Behring
4.5. F. Hoffmann-La Roche Ltd.
4.6. Kedrion
4.7. Novo Nordisk A/S
4.8. Octapharma AG
4.9. Pfizer, Inc.
4.10. Shire Plc

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/ 

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.